Everybody loses in the end: Billion-dollar government prizes won't improve on market incentives

In his latest attempt to replace America's free market with government regulators to set prices for medicines, Senator Bernie Sanders wants to reward drug developers with cash prizes determined in Washington. In his vision, these would replace the current US patent system.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Zetia buyers secure backing for ‘market narrowing’ in MSD antitrust case

4 November 2021 Wholesale buyers of the cholesterol treatment Zetia have won the backing of a US judge for their market definition in an antitrust suit against MSD and Glenmark.

Generics

Repurposed drugs: protections and incentives

13 April 2021 Repurposing drugs has very clear benefits. It gives companies the opportunity to develop entirely new uses for existing drugs that they don’t have patent protection, and may allow innovator companies to protect a molecule or formulation even after initial patent protection has expired.

More features

AIPPI: Personalised medicine tests the limits in patent law

Ropes & Gray loses 21-attorney group to join rival on growth spree

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Everybody loses in the end: Billion-dollar government prizes won't improve on market incentives

More on this story

Editor's picks

Editor's picks

More features